Details
Stereochemistry | RACEMIC |
Molecular Formula | C17H23NO2.C4H4O4 |
Molecular Weight | 389.4422 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C\C(O)=O.CCOC(=O)[C@]1(CCC=C[C@@H]1N(C)C)C2=CC=CC=C2
InChI
InChIKey=PMBFJKOESQBPHB-BHDCFXIMSA-N
InChI=1S/C17H23NO2.C4H4O4/c1-4-20-16(19)17(14-10-6-5-7-11-14)13-9-8-12-15(17)18(2)3;5-3(6)1-2-4(7)8/h5-8,10-12,15H,4,9,13H2,1-3H3;1-2H,(H,5,6)(H,7,8)/b;2-1+/t15-,17+;/m0./s1
Approval Year
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15627429
The selectivity of tilidine and nortilidine for human opioid and opioid-like receptors stably expressed in CHO-K1 cells, using the inhibition of the forskolin (FK)-induced accumulation of cAMP as the endpoint was measured. In cells expressing the Mu opioid receptor, tilidine and nortilidine inhibited cAMP accumulation with IC50 of 11 microM and 110 nM, respectively.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
55567-81-2
Created by
admin on Fri Dec 15 15:20:10 GMT 2023 , Edited by admin on Fri Dec 15 15:20:10 GMT 2023
|
PRIMARY | |||
|
DXT828600R
Created by
admin on Fri Dec 15 15:20:10 GMT 2023 , Edited by admin on Fri Dec 15 15:20:10 GMT 2023
|
PRIMARY | |||
|
259-711-1
Created by
admin on Fri Dec 15 15:20:10 GMT 2023 , Edited by admin on Fri Dec 15 15:20:10 GMT 2023
|
PRIMARY | |||
|
76965455
Created by
admin on Fri Dec 15 15:20:10 GMT 2023 , Edited by admin on Fri Dec 15 15:20:10 GMT 2023
|
PRIMARY | |||
|
DTXSID4021349
Created by
admin on Fri Dec 15 15:20:10 GMT 2023 , Edited by admin on Fri Dec 15 15:20:10 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD